Shared Decision Making on Care Pathways and CAMs: A Pilot Study

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05388734
Collaborator
University Grenoble Alps (Other), Laboratoire TIMC-IMAG (Other)
100
2
2
11
50
4.6

Study Details

Study Description

Brief Summary

Shared Decision Making on Care Pathways and alternative and complementary medicine (CAMs) : A Pilot Study.

Study whose aim is to evaluate the feasibility of a study proposing a therapeutic education consultation leaning on the usual care pathway by estimating the recruitment capacity over 4 months as well as the acceptance rate of the study among patients diagnosed with breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: alternative medicine education consultation
N/A

Detailed Description

The use of alternative and complementary medicine (CAMs) has been steadily increasing for several years. Certain populations are more likely than others to use this type of care, including breast cancer patients, for whom the rate of use is close to 90%. However, these populations are those for whom the risks associated with this type of care are the highest. In addition, patients rarely discuss alternative and complementary medicine (CAMs) with conventional care teams. As a result, patients often place unreasonable expectations on alternative and complementary medicine (CAMs) and at the same time put themselves in risky situations.

The aim of this project is to help breast cancer patients better orient themselves in their care pathway and in particular with regard to the plethora of alternative and complementary medicine (CAMs) available. They could therefore make an informed decision to seek (or not) treatment. In order to reach a shared decision, a consultation will be offered to patients with the objective of discussing their past recourse, their knowledge of the care pathway, their fears and their aspirations with regard to alternative and complementary medicine (CAM). Epistemological concepts (self-efficacy, placebo, benefit-risk ratio, etc.) will be discussed in order to allow these elements to be transposed throughout their care.

The impact of this consultation on compliance with conventional treatment, satisfaction with the treatment as a whole and communication with the rest of the health care team will be evaluated. A before/after methodology will first allow us to evaluate the values taken by our judgement criteria in the usual care pathway and then in the innovative care pathway proposed by the intervention. This study will allow us to establish the feasibility of a future research project of larger scale.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Quasi-experimental, before-and-after, comparative, prospective, single-center, open-label study.Quasi-experimental, before-and-after, comparative, prospective, single-center, open-label study.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Shared Decision Making on Care Pathways and CAMs: A Pilot Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Before group

Patients in the before group are recruited during the first 4 months of the study and will not benefit from the alternative medicine education consultation

Active Comparator: After Group

Patients in the front group are recruited from the 5th month of the study and will benefit from the alternative medicine education consultation

Other: alternative medicine education consultation
The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of a study proposing a therapeutic education consultation linked to the usual course of care [8 month]

    The investigators wish know the recruitment capacity in this study. To do this, the investigators will estimate the number of people included over 8 months (time of recruitment in the study).

Secondary Outcome Measures

  1. Evaluate literacy in the care pathway. [inclusion, 6 month]

    "Health Literacy Questionnaire" (HLQ) at 6 month post intervention. Questionnaire contains 2 parts : P1 with 23 questions, and P2 with 21 questions. Coding: P1Q1 to P1Q23 Strongly Disagree = 1 Disagree = 2 Agree = 3 Strongly Agree = 4 P2Q1 to P2Q21 Cannot do or always difficult, = 1 Usually difficult = 2 Sometimes difficult = 3 Usually easy = 4 Always easy = 5 The HLQ consists of 9 scales representing 9 dimensions of health literacy. Each HLQ scale has 4-6 items. The HLQ does not provide one overall summative score. The scoring of the HLQ is 9 scale scores, calculated by averaging the item scores within each scale with equal weighting. The 9 scale scores will reflect a person's strengths and needs in the different dimensions of health literacy. For Scales 1 to 5, the score range is between 1 and 4 For Scales 6 to 9, the score range is between 1 and 5

  2. Satisfaction with improvement in orientation to the care pathway [6 month]

    To assess the HQL (Health Literacy Questionnaire) Minimal Clinically Interesting Difference at 6 months after the intervention. The investigators wish to assess the Minimal Clinically Interesting Difference at 6 months after the intervention by comparing the response about the satisfaction with improvement in orientation to the care pathway (0: No improvement, 1 : Slight improvement, 2 : Good improvement, 3 : Excellent improvement) " to the HLQ dimensions of interest.

  3. Success in orienting to the care pathway [inclusion, 6 month]

    The investigators wish to assess PALS by comparing the response to the question "Do you feel able to learn about services and supports to ensure that all your health needs are met? ( YES/NO)" to the HLQ dimensions of interest. PALS will be binary, either patients feel able to orient themselves in the care pathway or they do not feel able to do so

  4. Assess satisfaction with the current care pathway [6 month]

    Bilateral 6-item Likert scale at 6 months after surgery (-3: very dissatisfied to +3 very satisfied )

  5. Collect the patient experience [6 month]

    Semi-directive interview conducted at 6 months after the intervention. This interview will be carried out only for some patients of the study until data saturation.

  6. To assess patient adherence, patient believes in the mechanics of TACs operation. [inclusion, 6 month]

    CHBQ questionnaire completed at inclusion (pre-intervention) and at 6 months (post-intervention by the patient. This questionnaire is composed of 10 propositions. The total score varies between 10 (total disagreement with all the proposals) and 70 (total agreement with all the proposals). The authors suggest that above the median score of 40, the respondent has a positive attitude towards TACs and conversely a negative attitude towards TACs for a score below 40.

  7. To assess co-variance between oncologist and patient beliefs in TACs operating mechanisms [Inclusion]

    CHBQ questionnaire completed by the oncologist at the beginning of the study (before the start of the inclusion). This questionnaire is composed of 10 propositions. The total score varies between 10 (total disagreement with all the proposals) and 70 (total agreement with all the proposals). The authors suggest that above the median score of 40, the respondent has a positive attitude towards TACs and conversely a negative attitude towards TACs for a score below 40.

  8. To assess the use of TACs [inclusion, 6 month]

    If individuals have used TACs, then they are offered a simplified and adapted version of the CAMP-Q (Complementary and Alternative Medicine Practitioner Use Questionnaire) completed at inclusion and 6 months after the intervention by the patient. This questionnaire includes 49 questions and the objective will be to evaluate if the patient has used one or more alternative medicines (1) or no alternative medicine (0). It don't have a rating

  9. To assess satisfaction with TACs [inclusion, 6 month]

    Bilateral 6-item Likert scale (-3: very dissatisfied to +3 very satisfied) at baseline and 6 months after the procedure ONLY if at least one complementary alternative technique was checked in answer n°1 of the CAMP Q questionnaire. This is to have a before and after evaluation.

  10. To assess satisfaction with oncology care. [6 month]

    Two-sided 6-item Likert scale (-3: very dissatisfied to +3 very satisfied ) at 6 months post intervention. These goals are only evaluated for patients in the AFTER group

  11. Assess patient satisfaction with the procedure. [After intervention, 6 month]

    Two-way 6-item Likert scale (-3: very dissatisfied to +3 very satisfied ) evaluated after the intervention and at 6 months. This objective is only evaluated for patients in the AFTER group

  12. Assess patient recommendation of the intervention [After intervention, 6 month]

    Two-way Likert scale with 4 items (-2 not at all agree to +2 completely agree ) evaluated after the intervention and at 6 months. This objective is only evaluated for patients in the AFTER group

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients recently diagnosed with breast cancer at Grenoble Alpes University Hospital

  • In situ or invasive breast cancer, locally advanced but without metastasis, demonstrated on histology

  • ECOG ( Eastern Cooperative Oncology Group) performance status 0, 1 or 2

  • Cancer treated with chemotherapy, radiotherapy and/or surgery

  • Having signed an informed consent after information, being of age and able to express consent, affiliated to a social security system

Exclusion Criteria:
  • Pregnant, breastfeeding or parturient women

  • women who do not speak French;

  • patients participating in another research protocol

  • Metastatic breast cancer, diagnosed psychiatric pathologies that make it impossible to perform the procedure, history of cancer except for cervical cancer in situ or basal cell cancer

  • Subjects in a period of exclusion from another study,

  • Subject under administrative or judicial supervision

  • Subject unable to be contacted in case of emergency

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chu Grenoble Grenoble France 38000
2 Pole Sante Saint Martin D'Heres Saint-Martin-d'Hères France 38400

Sponsors and Collaborators

  • University Hospital, Grenoble
  • University Grenoble Alps
  • Laboratoire TIMC-IMAG

Investigators

  • Principal Investigator: NICOLAS PINSAULT, University Hospital, Grenoble

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT05388734
Other Study ID Numbers:
  • 2021-A03027-34
First Posted:
May 24, 2022
Last Update Posted:
Jul 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Grenoble
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2022